Incyte (INCY) Stock Price, News & Analysis

Company Overview

Incyte Corporation is a Wilmington, Delaware–based biopharmaceutical company focused on the discovery, development and commercialization of novel therapies in oncology and inflammation. Since its founding in 2002, Incyte has grown from a small research organization into a global enterprise, advancing a portfolio of internally developed and partnered assets. The company’s research and development efforts center on small-molecule drugs and biologics that modulate critical signaling pathways implicated in cancer, autoimmune disorders and rare diseases.

The company’s flagship product is Jakafi® (ruxolitinib), a Janus kinase (JAK) inhibitor approved for the treatment of myelofibrosis and polycythemia vera. Incyte has expanded its JAK franchise with the topical formulation Opzelura® (ruxolitinib cream), which is approved for atopic dermatitis and vitiligo. Beyond JAK inhibition, the company maintains a deep pipeline that includes programs targeting IDO1, PI3Kδ and PD-1/PD-L1, among other mechanisms, with candidates in various stages of clinical development.

Incyte conducts clinical trials and commercial operations across North America, Europe and the Asia-Pacific region. The company has established strategic collaborations and licensing agreements with several global partners to extend its reach and leverage complementary expertise in regulatory affairs, manufacturing and marketing.

Leadership at Incyte is headed by President and Chief Executive Officer Hervé Hoppenot, who brings extensive experience in global biopharmaceutical management. Under his stewardship, the company continues to prioritize innovation, rigorous clinical investigation and patient access to new therapies.

Key Stats

• Today's Range: $94.10 to $96.36
• 50-Day Range: $90.30 to $100.32
• 52-Week Range: $63.51 to $112.29
• Volume: 206,211 shs
• Average Volume: 1.70 million shs
• Market Capitalization: $19.19 billion
• P/E Ratio: 13.52
• Dividend Yield: N/A
• Price Target: $104.26
• Consensus Rating: Hold

Incyte Stock Analysis - MarketRank™

Incyte scored higher than 93% of companies evaluated by MarketBeat, and ranked 41st out of 859 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.0 / 5
• Analyst Rating: Hold

Consensus Rating

Incyte has received a consensus rating of Hold. The company's average rating score is 2.43, and is based on no strong buy ratings, 10 buy ratings, 10 hold ratings, and 1 sell rating.

Upside/Downside

The consensus price target for Incyte is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Incyte has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 4.4 / 5
• Proj. Earnings Growth: 17.95%

Earnings Growth

Earnings for Incyte are expected to grow by 17.95% in the coming year, from $6.74 to $7.95 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Incyte is 13.46, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.39.

Price to Earnings Ratio vs. Sector

The P/E ratio of Incyte is 13.46, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 20.62.

Price to Earnings Growth Ratio

Incyte has a PEG Ratio of 0.91. PEG Ratios below 1 indicate that a company could be undervalued.

Price to Book Value per Share Ratio

Incyte has a P/B Ratio of 3.62. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

6.78% of the float of Incyte has been sold short.

Short Interest Ratio / Days to Cover

Incyte has a short interest ratio ("days to cover") of 7.05.

Change versus previous month

Short interest in Incyte has recently decreased by 5.15%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Incyte does not currently pay a dividend.

Dividend Growth

Incyte does not have a long track record of dividend growth.

News and Social Media

• Score: 3.9 / 5
• News Sentiment: 1.25

News Sentiment

Incyte has a news sentiment score of 1.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.35 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Incyte this week, compared to 10 articles on an average week.

Search Interest

23 people have searched for INCY on MarketBeat in the last 30 days. This is an increase of 77% compared to the previous 30 days.

MarketBeat Follows

8 people have added Incyte to their MarketBeat watchlist in the last 30 days. This is an increase of 60% compared to the previous 30 days.

Company Ownership

• Score: 2.0 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Incyte insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,560,544.00 in company stock.

Percentage Held by Insiders

16.20% of the stock of Incyte is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

96.97% of the stock of Incyte is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 4/28/2026
• Today: 5/19/2026
• RBC Capital Markets Global Healthcare Conference 2026: 5/19/2026
• Next Earnings (Estimated): 8/04/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:INCY
• CIK: 879169
• Web: www.incyte.com
• Phone: (302) 498-6700
• Fax: 302-425-2750
• Employees: 2,844
• Year Founded: 1991

Price Target and Rating

• Average Price Target for Incyte: $104.26
• High Price Target: $135.00
• Low Price Target: $60.00
• Potential Upside/Downside: +8.5%
• Consensus Rating: Hold
• Rating Score (0-4): 2.43
• Research Coverage: 21 Analysts

Profitability

• EPS (Trailing Twelve Months): $7.08
• Trailing P/E Ratio: 13.58
• Forward P/E Ratio: 14.26
• P/E Growth: 0.91
• Net Income: $1.29 billion
• Net Margins: 26.71%
• Pretax Margin: 33.09%
• Return on Equity: 26.66%
• Return on Assets: 19.77%

Debt

• Debt-to-Equity Ratio: 0.01
• Current Ratio: 3.68
• Quick Ratio: 3.60

Sales & Book Value

• Annual Sales: $5.14 billion
• Price / Sales: 3.74
• Cash Flow: $6.23 per share
• Price / Cash Flow: 15.42
• Book Value: $26.32 per share
• Price / Book: 3.65

Miscellaneous

• Outstanding Shares: 199,780,000
• Free Float: 167,417,000
• Market Cap: $19.20 billion
• Optionable: Optionable
• Beta: 0.79